Bengaluru: Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, has received the initial authorization from European Medicine Agency (EMA), recommending the grant of the final Marketing Authorization for the company’s medicinal product, Rivaroxaban 10 mg, 15 mg, and 20 mg Orodispersible Films. Shilpa’s Rivaroxaban Orodispersible Films is an anticoagulant medicine (a medicine that prevents blood clotting). This approval has come from the Company’s finished dosage form manufacturing facility, Shilpa Medicare Ltd, Unit VI, located at Dabaspet, Bengaluru, Karnataka. Shilpa Medicare is a global pharmaceutical company specializing in contract development and manufacturing services for small and large molecules. Shilpa Medicare operates R&D and manufacturing facilities, serving partners across North America, Europe, and Asia.